From the Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Exp Clin Transplant. 2023 Jan;21(1):70-75. doi: 10.6002/ect.2022.0081.
Congenital sideroblastic anemia is characterized by anemia and intramitochondrial iron accumulation in erythroid precursors that form ring sideroblasts. The most common recessive forms are caused by sequence variations in the ALAS2 and SLC25A38 genes. In patients with transfusion-dependent and pyridoxine- resistant severe congenital sideroblastic anemia, hematopoietic stem celltransplantis the only curative option. Herein, we described successful implementations of allogeneic hematopoietic stem cell transplant in 4 Iranian children with congenital sideroblastic anemia. The patients had presented with clinical manifestations of anemia early in life, and the diagnoses of congenital sideroblastic anemia were established through blood tests and bone marrow aspiration. Congenital sideroblastic anemia was further confirmed by the identification of pathogenic variants in SLC25A38 in 2 patients. All 4 patients received allogeneic hematopoietic stem cell transplant with myeloablative conditioning regimen that included busulfan, cyclophosphamide, andrabbit antithymocyte globulin. A combination of cyclosporine A and methotrexate or mycophenolate mofetil was used for graft-versus-host disease prophylaxis. Bone marrow and peripheral blood from sibling or related donors with fully matched human leukocyte antigen profiles were applied. The outcomes of hematopoietic stem celltransplantin patients with congenital sideroblastic anemia were favorable. Three patients achieved full donor chimerism (>95%, 98%, and 100%), and the other patient showed mixed chimerism (75%). All patients remained transfusion independent. Hemato- poietic stem celltransplantis a curative treatmentthat can provide long-term survival for patients with congenital sideroblastic anemia, particularly when used in a timely manner. There remain ongoing challenges in various aspects of hematopoietic stem celltransplantin patients with congenital sideroblastic anemia, which remain to be elucidated.
先天性铁粒幼细胞性贫血的特征是红系前体细胞贫血和线粒体铁蓄积,形成环形铁幼粒细胞。最常见的隐性形式是由 ALAS2 和 SLC25A38 基因的序列变异引起的。在依赖输血和吡哆醇耐药的严重先天性铁粒幼细胞性贫血患者中,造血干细胞移植是唯一的治愈选择。在此,我们描述了 4 例伊朗先天性铁粒幼细胞性贫血患者成功实施异基因造血干细胞移植的情况。这些患者在生命早期就出现了贫血的临床表现,通过血液检查和骨髓抽吸确定了先天性铁粒幼细胞性贫血的诊断。2 例患者通过鉴定 SLC25A38 中的致病性变异进一步证实了先天性铁粒幼细胞性贫血的诊断。所有 4 例患者均接受了含白消安、环磷酰胺和兔抗胸腺细胞球蛋白的清髓性预处理方案的异基因造血干细胞移植。环孢素 A 和甲氨蝶呤或霉酚酸酯的联合用于移植物抗宿主病的预防。应用来自与患者完全匹配人类白细胞抗原图谱的同胞或相关供者的骨髓和外周血。先天性铁粒幼细胞性贫血患者的造血干细胞移植结果良好。3 例患者获得完全供者嵌合体(>95%、98%和 100%),另 1 例患者显示混合嵌合体(75%)。所有患者均无需输血。造血干细胞移植是一种可以为先天性铁粒幼细胞性贫血患者提供长期生存的治愈性治疗方法,特别是在及时应用的情况下。在先天性铁粒幼细胞性贫血患者的造血干细胞移植的各个方面仍然存在挑战,有待进一步阐明。